Steroids remain an essential part of immunosuppressive therapy for renal transplant patients since the start of transplant era. Different immunosuppressive regimens are prescribed so as to minimize the side effects. The purpose of our study is to compare the outcome of early steroid withdrawal with steroid maintenance protocol. It is a prospective nonrandomized study. All patients that received renal transplants from January 2011 to December 2013 were included in the study. Early steroid withdrawal at day 5 was done in low immunological risk patients, and the results were compared with the steroid maintenance group, at one-year, posttransplant. Outcome measures included acute rejection (AR), slow graft function and delayed graft function (SGF and DGF), patient and graft survival, and new-onset diabetes after transplant (NODAT), dyslipidemia, hypertension, and obesity. A total of 249 patients were divided into two groups -105 patients had early steroid withdrawal and 144 patients were maintained on steroid therapy. Outcome measures were compared one-year posttransplant. There was no significant difference in AR, patient and graft survival, creatinine level, and weight gain. However, a significant difference in systolic and diastolic blood pressure, lipid profile, NODAT, SGF, and DGF was found in the steroid group. Our study shows that early steroid withdrawal is a safe standard of care in low immunological risk patients.
Introduction
Steroids have remained an essential part of posttransplant maintenance therapy since the Correspondence to:
adverse effects cost US $5300 per patient per year. Later, with the introduction of new immunosuppressive drugs such as tacrolimus (FK), mycophenolate mofetil (MMF), sirolimus, and antibodies as induction therapy, the scenario changed. Transplant physicians got a number of new immunosuppressive therapy options. This led to both the physicians and the patients, opting for steroid-free regimens in organ transplant cases. [4] [5] [6] However, previous reviews [6] [7] [8] showed that steroid avoidance protocols led to increased incidence of complications, i.e., acute graft rejection and decreased graft survival at five years. 9, 10 Majority of the steroid-free regimens prescribed nowadays include either steroid avoidance or early withdrawal within five to seven days posttransplant.
Methods

Study design
It is a prospective nonrandomized study. All patients that received renal transplant at our center from January 2011 to December 2013 were included in the study. Patients were followed up for one-year posttransplant. No protocol biopsy was taken.
Eligibility criteria
All patients aged 14 years and above, who received either live related (LR), live nonrelated (LNR), or deceased donor (DD) kidney was included and was divided into an early steroid withdrawal (at day 5) group and a steroid maintenance group. Patients with low immunological risk and patients with diabetes or a strong family history of DM were selected for early steroid withdrawal regimen.
Immunosuppression
Almost all our patients received antithymocyteglobulin (ATG) (except a few) as induction therapy along with pulse steroids. Dose for ATG was 1.5 mg/kg/dose (maximum aggregate dose up to 6 mg /kg); adjusted as per white blood cell, platelet and lymphocyte count. Steroids were withdrawn on day 5 posttransplant in patients in the early steroid withdrawal group. Both groups remained on FK/MMF. FK levels were kept the same in both groups.
Primary and secondary endpoints
Our primary endpoints were acute rejection (AR), patient, and graft survival. Graft survival was also taken as a secondary endpoint. Dyslipidemia, new-onset diabetes after transplant (NODAT), weight gain, and changes in blood pressure were taken as safety endpoints.
Statistical Analysis
Independent sample t-test was done for continuous variable and Chi-square/Fisher's exact test for categorical variables to assess the baseline difference between the two groups. The log-rank test was used for assessing survival differences between the two groups. The graphical and statistical tests did not indicate the violation of proportional hazard assumption. Statistical significance was set to 0.05, and Statistical Package for the Social Sciences version 20.0 (IBM Corp., Armonk, NY, USA) was used for analysis.
Results
From January 2011 to December 2013, 249 patients aged14 and above (age range 14-80 years, of which 50% recipients were between 31-50 years of age) received renal transplants, from male/female live LR, LNR and DDs at Prince Sultan Military Medical City, Riyadh, ( Figure 1 ). Of these 249 patients, 105 patients (42%) were considered for early withdrawal protocol, while 144 patients (58%) were kept on steroid maintenance therapy. All of the patients received ATG and pulse steroid as induction therapy and were maintained on FK/MMF. Male to female ratio was 79:21 in the early steroid withdrawal group, whereas in steroid maintenance group, the ratio was 63:37. In steroid withdrawal group 82% received LR, 9.5% received LNR and 8.5% received DDs, whereas in the other group 40% received LR, 28% received LNR, and 32% received DDs. (Figure 2 ). Of 144 patients in the early steroid withdrawal group, 4 patients were lost to follow-up.
In the early steroid maintenance group, 10 patients lost to follow-up within one year and one patient died of pulmonary tuberculosis eight months' posttransplant. There was no significant difference in acute graft rejection and graft survival in patients of both groups at one year follow-up. In both groups, AR rate was the same (10%). Those patients, in early steroid withdrawal group, who had graft rejection within three months posttransplant were shifted to steroid maintenance therapy.
At one year follow-up, no differences in serum creatinine levels and weight gain were seen among patients of both groups. However, statistically significant rise in systolic blood pressure (SBP) (6.33 vs. 22.13 mm Hg) and diastolic blood pressure (DBP) (mean 3.11 mm Hg vs. 9.46 mm Hg) was found. Moreover, a significant increase in lipid profile was noticed in patients on steroid maintenance therapy. The incidence of NODAT was higher in steroid-dependent group (6.6% vs. 11.5%). Slow graft function and delayed graft function (SGF and DGF) was found more in steroiddependent group (Table 1 and Figure 3 ). DSA positivity at one year was higher in steroiddependent group in both cadaveric and living ( Figure 4 ). Mismatch more than four was also Figure 5 ). New-onset proteinuria found to be slightly higher in steroid-dependent cadaveric recipients, although majority of patients had no follow-up proteinuria ( Figure 6 ) graft survival rate at one year was the same in both groups (Figure 7 ).
Discussion
Steroid maintenance therapy is still used extensively in majority of kidney transplant centers across the world. 11, 12 Although now, a shift toward either steroid avoidance or early withdrawal at day 5-day 7 posttransplant is gathering momentum; the reason being the adverse effects caused by prolonged use of low dose steroids (<7.5 mg/d) such as weight gain, dyslipidemia, acne, bruises, gastritis, and so on. 3, 4 A meta-analysis by Pascual et al 13 has confirmed that steroid avoidance or withdrawal is possible in low immunological risk transplant recipients.
In this study, we did not find any difference in AR rate in both groups at one-year followup. A similar result was shown in DOMINOS study, 14 though the comparison was between steroid-free and steroid withdrawal regimens. On the contrary, Vincenti et al showed that there was a higher incidence of AR in both steroid-free and steroid withdrawal regimens as compared to steroid-dependent regimens (P = 0.004) at one-year follow-up. However, graft survival was the same in both groups at one year. 15 Other trials by Vítko et al 16 and another multicenter prospective trial 17 showed a higher rate of acute rejection in steroid-free and steroid withdrawal group, respectively. However, the results of multiple studies show no difference in AR when calcineurin inhibitor (CNI) was used in combination with MMF and antibody induction. [18] [19] [20] Rostaing et al compared Dacluzimab/Tacrolimus (TAC)/MMF with TAC/MMF/Steroid and found AR rate at six months to be same (16.5%) in both groups. 18 Although in the study, the steroid maintenance group did not receive antibody and was given a higher TAC dosage. Sureshkumar et al have showed in OPTN/UNOS database that, the use of ATG as an induction agent was associated with better graft survival 21 and AR rate was less with CNI/MMF/steroid-free regimen compared with induction with interleukin-2 receptor antagonist.
In our study, we used ATG and pulse steroid as induction therapy, followed by steroid withdrawal at day 5 posttransplant. Among full house match patients, 14 patients were given steroid only while seven others were given basiliximab along with steroids. Our rejection rate in both groups was 10% over one year, irrespective of varying induction therapies with similar TAC levels in both groups. (ATG/ TAC/MMF/Steroid vs. ATG/TAC/MMF). No difference was found in graft and patient survival at one year. Our findings are same as those published by Woodle and Fuysane Steroid withdrawal study group. 22 In that study, a total of 396 patients were enrolled and randomly assigned to TAC/MMF/Steroid or TAC/ MMF/steroid withdrawal at day 7; although, in this study, the AR was different from ours (6% vs. 12% steroid-dependent and steroid withdrawal groups). The results of our study are also substantiated by other studies. [15] [16] [17] [18] [19] 23, 24 Serum creatinine levels were better in steroid withdrawal group at three and six months follow-up, although at one-year follow-up no significant difference was found in both groups. This was assumed to be due to selection criteria (low immunological risk patient, low number of cadaveric transplants, and low number of extended criteria donor in steroid withdrawal group). A recent meta-analysis 25 of steroid-free kidney transplant patients found that this regimen was associated with higher risk of AR and rise in creatinine level but the same risk of death or graft failure in both groups. This study showed a significant rise in both systolic and DBPs, lipid profile, and NODAT in steroid maintenance group. The same group showed a higher occurrence of SGF/DGF (1% vs. 9% and 3% vs. 12%, respectively). The reason for which could be a higher percentage of the group receiving DD kidneys, where factors such as increased cold ischemia time may have contributed to the slow or delayed graft function. TAC levels were kept at the same range in both groups, and no difference in CNI toxicity was observed.
Another observation of this study, which is also corroborated by many other previous studies is that majority of kidney transplant recipients were males. 26 It might be due to unsuitability of the female recipients because of multiparity or unwilling of females to accept donation from close relatives. AR was more common in cadaveric group 22% versus 9%. AR, DGF, SGF, and NODAT all was common in female recipients. We are unable to explain this.
In literature, posttransplant new-onset proteinuria varies between 15% and 45%. 27 In our study, we found similar results with no significant difference between two groups. Although we had a high percentage of patients with no follow-up proteinuria as it was not included in primary or secondary outcome. More than four HLA mismatch was higher in steroid-dependent group, both in cadaveric and living related. We could not find any significant difference in DSA at one-year follow-up in two groups, although the percentage was slightly higher in steroid-dependent group.
There was no cytomegalovirus (CMV) and polyomavirus (BK) infection in steroid-free group whereas five cases of CMV viremia and one case of BK viremia and one case of BK nephropathy in steroid-dependent group. All patients receive CMV prophylaxis for three to six months. Mean cold ischemia time in cadaveric transplant was 12.5 h with a range between 2 and 21 h and median of 10 h. It is not comparable between two groups, as the number of cadaveric transplant in steroid-free was less.
Various studies show that the risk of AR increases if antibodies are not used in induction therapy. 28, 29 In this study, contrarily, no increase in AR was seen using only steroid as induction therapy in full house match patients.
This study, nonetheless, has some limitations. It is a nonrandomized study; moreover, the follow-up duration is short. The study is being extended for up to 10 years' follow-up, to see the outcome regarding chronic rejection ratio, and graft as well as patient survival.
Conclusion
The study suggests that in low immunological risk patients, ATG induction followed by TAC, MMF, and steroid withdrawal at day 5 posttransplant is a fairly safe regimen. This regimen gives better metabolic outcome and similar graft and patient survival, provided patient selection is made carefully. The study also shows that methylprednisolone induction alone is quite safe in well-selected full house match patients. On account of these findings, we suggest that all cadaveric renal transplants should be placed on steroid-based maintenance regimen. In a patient on steroid-free regimen, a rejection within three months posttransplant warrants a shift to steroid maintenance therapy. On the other hand, if the rejection occurs after three months posttransplant, it can be treated with pulse steroids and the patient can be continued on steroid-free regimen.
This study also finds it safe to keep TAC level in the same range in both groups.
Finally, more long-term studies are needed to validate the safety of steroid-free or early steroid withdrawal regimens on a long-term basis.
